<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: sets forth risk factors", fill: "#0067a5"},
{source: "1: sets forth risk factors", target: "1: Companys ", fill: "#0067a5"},
{source: "1: Companys ", target: "1: differ materially from", fill: "#0067a5"},
{source: "1: differ materially from", target: "1: Annual Report ", fill: "#0067a5"},
{source: "1: Annual Report ", target: "1: Form ", fill: "#0067a5"},
{source: "1: sets forth risk factors", target: "7: must go through", fill: "#2c1608"},
{source: "7: must go through", target: "7: preclinical animal", fill: "#2c1608"},
{source: "7: preclinical animal", target: "7: clinical human trials", fill: "#2c1608"},
{source: "7: clinical human trials", target: "7: effective", fill: "#2c1608"},
{source: "7: effective", target: "7: commercialized", fill: "#2c1608"},
{source: "7: must go through", target: "12: current regulatory framework could", fill: "#002395"},
{source: "12: current regulatory framework could", target: "12: additional regulations could", fill: "#002395"},
{source: "12: additional regulations could", target: "12: stage during", fill: "#002395"},
{source: "12: stage during", target: "12: product development", fill: "#002395"},
{source: "12: product development", target: "12: marketing which may affect", fill: "#002395"},
{source: "12: marketing which may affect", target: "12: significant", fill: "#002395"},
{source: "12: significant", target: "12: expenditures", fill: "#002395"},
{source: "12: current regulatory framework could", target: "18: the Companys ", fill: "#03a"},
{source: "18: the Companys ", target: "18: drug candidates may prove", fill: "#03a"},
{source: "18: drug candidates may prove", target: "18: ineffective", fill: "#03a"},
{source: "18: ineffective", target: "18: commercialization", fill: "#03a"},
{source: "18: the Companys ", target: "19: The Company ", fill: "#8a496b"},
{source: "19: The Company ", target: "19: strict governmental regulation", fill: "#8a496b"},
{source: "19: The Company ", target: "23: from preclinical", fill: "#483c32"},
{source: "23: from preclinical", target: "23: clinical trials may", fill: "#483c32"},
{source: "23: clinical trials may", target: "23: varying interpretations which", fill: "#483c32"},
{source: "23: varying interpretations which", target: "23: delay limit", fill: "#483c32"},
{source: "23: delay limit", target: "23: relevant governmental authority", fill: "#483c32"},
{source: "23: from preclinical", target: "25: Agencies ", fill: "#fff700"},
{source: "25: Agencies ", target: "25: endpoints", fill: "#fff700"},
{source: "25: endpoints", target: "25: clinical trials", fill: "#fff700"},
{source: "25: clinical trials", target: "25: accepted by", fill: "#fff700"},
{source: "25: accepted by", target: "25: begun clinical data may", fill: "#fff700"},
{source: "25: Agencies ", target: "30: The Company ", fill: "#faf0be"},
{source: "30: The Company ", target: "30: faces vigorous competition", fill: "#faf0be"},
{source: "30: faces vigorous competition", target: "30: drug discovery", fill: "#faf0be"},
{source: "30: drug discovery", target: "30: development", fill: "#faf0be"},
{source: "30: development", target: "30: commercializing", fill: "#faf0be"},
{source: "30: commercializing", target: "30: successfully than", fill: "#faf0be"},
{source: "30: The Company ", target: "39: competitors either alone", fill: "#841b2d"},
{source: "39: competitors either alone", target: "39: together with", fill: "#841b2d"},
{source: "39: together with", target: "39: collaborative partners", fill: "#841b2d"},
{source: "39: collaborative partners", target: "39: larger research", fill: "#841b2d"},
{source: "39: larger research", target: "39: development programs", fill: "#841b2d"},
{source: "39: development programs", target: "39: substantially greater", fill: "#841b2d"},
{source: "39: substantially greater", target: "39: financial resources", fill: "#841b2d"},
{source: "39: financial resources", target: "39: regulatory", fill: "#841b2d"},
{source: "39: regulatory", target: "39: formulating", fill: "#841b2d"},
{source: "39: formulating", target: "39: manufacturing", fill: "#841b2d"},
{source: "39: manufacturing", target: "39: commercializing", fill: "#841b2d"},
{source: "39: commercializing", target: "39: the Company ", fill: "#841b2d"},
{source: "39: competitors either alone", target: "42: The Company ", fill: "#a7fc00"},
{source: "42: The Company ", target: "42: depended on", fill: "#a7fc00"},
{source: "42: depended on", target: "42: collaborative partners", fill: "#a7fc00"},
{source: "42: collaborative partners", target: "42: significant", fill: "#a7fc00"},
{source: "42: significant", target: "42: development expenses", fill: "#a7fc00"},
{source: "42: development expenses", target: "42: manufacture", fill: "#a7fc00"},
{source: "42: manufacture", target: "42: collaborations", fill: "#a7fc00"},
{source: "42: The Company ", target: "START_HERE", fill: "#a7fc00"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Passeig_de_Lluís_Companys,_Barcelona">Passeig de Lluís Companys, Barcelona</a></td>
      <td>Passeig de Lluís Companys (Catalan pronunciation: [pəˈsɛdʒ də ʎuˈis kumˈpaɲs]) is a promenade in the Ciutat Vella and Eixample districts of Barcelona, Catalonia, Spain, and can be seen as an extension of Passeig de Sant Joan. It was named after President Lluís Companys, who was executed in 1940.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Estadi_Olímpic_Lluís_Companys">Estadi Olímpic Lluís Companys</a></td>
      <td>Estadi Olímpic Lluís Companys (Catalan pronunciation: [əsˈtaði uˈlimpiɡ ʎuˈis kumˈpaɲs], formerly known as the Estadi Olímpic de Montjuïc and Estadio de Montjuic) is a stadium in Barcelona, Catalonia, Spain. Originally built in 1927 for the 1929 International Exposition in the city (and Barcelona's bid for the 1936 Summer Olympics, which were awarded to Berlin), it was renovated in 1989 to be the main stadium for the 1992 Summer Olympics and 1992 Summer Paralympics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_largest_companies_in_the_United_States_by_revenue">List of largest companies in the United States by revenue</a></td>
      <td>This list comprises the largest companies in the United States by revenue as of 2022, according to the Fortune 500 tally of companies. Retail corporation Walmart has been the largest company in the US by revenue since 2014.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Conxita_Julià">Conxita Julià</a></td>
      <td>Conxita Julià i Farrés (Catalan pronunciation: [kuɲˈʃitə ʒuliˈa j fəˈres]; 11 June 1920 – 9 January 2019), also known as Conxita de Carrasco, was a Catalan woman noted for her dealings with Lluís Companys, President of Catalonia, in the 1930s, and for her poetry. Julià died in January 2019 at the age of 98.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Víctor_Gay_Zaragoza">Víctor Gay Zaragoza</a></td>
      <td>Víctor Gay Zaragoza (born 19 June 1982 in Barcelona, Spain) is a writer, storyteller, trainer and consultant on storytelling. He is author of the essays "Filosofía Rebelde" (Rebel Philosophy), "50 libros que cambiarán tu vida" (50 books that will change your life) and the historical novel "El defensor" (The defender).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_figures">Significant figures</a></td>
      <td>Significant figures (also known as the significant digits, precision or resolution) of a number in positional notation are digits in the number that are reliable and necessary to indicate the quantity of something.\nIf a number expressing the result of a measurement (e.g., length, pressure, volume, or mass) has more digits than the number of digits allowed by the measurement resolution, then only as many digits as allowed by the measurement resolution are reliable, and so only these can be significant figures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_other">Significant other</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bit_numbering">Bit numbering</a></td>
      <td>In computing, bit numbering is the convention used to identify the bit positions in a binary number.\n\n\n== Bit significance and indexing ==\n\nIn computing, the least significant bit (LSB) is the bit position in a binary integer representing the binary 1s place of the integer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Significant_Others">Significant Others</a></td>
      <td>The term significant other (SO) has different uses in psychology and in colloquial language. Colloquially "significant other" is used as a gender-neutral term for a person's partner in an intimate relationship without disclosing or presuming anything about marital status, relationship status, gender identity, or sexual orientation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Statistical_significance">Statistical significance</a></td>
      <td>In statistical hypothesis testing, a result has statistical significance when it is very unlikely to have occurred given the null hypothesis. More precisely, a study's defined significance level, denoted by \n  \n    \n      \n        α\n      \n    \n    {\displaystyle \alpha }\n  , is the probability of the study rejecting the null hypothesis, given that the null hypothesis is true; and the p-value of a result, \n  \n    \n      \n        p\n      \n    \n    {\displaystyle p}\n  , is the probability of obtaining a result at least as extreme, given that the null hypothesis is true.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/East_India_Company">East India Company</a></td>
      <td>The East India Company (EIC) was an English, and later British, joint-stock company founded in 1600. It was formed to trade in the Indian Ocean region, initially with the East Indies (the Indian subcontinent and Southeast Asia), and later with East Asia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Pokémon_Company">The Pokémon Company</a></td>
      <td>The Pokémon Company (株式会社ポケモン, Kabushiki gaisha Pokémon) is a Japanese company responsible for brand management, production, publishing, marketing and licensing of the Pokémon franchise, which consists of video game software, a trading card game, anime television series, films, manga, home entertainment products, merchandise, and other ventures. It was established through a joint investment by the three businesses holding the copyright of Pokémon: Nintendo, Game Freak, and Creatures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Weather_Company">The Weather Company</a></td>
      <td>The Weather Company is a weather forecasting and information technology company that owns and operates weather.com and Weather Underground. The Weather Company has been a subsidiary of the Watson &amp; Cloud Platform business unit of IBM since 2016.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Honest_Company">The Honest Company</a></td>
      <td>The Honest Company, Inc. is an American consumer goods company, founded by actress Jessica Alba.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Longaberger_Company">The Longaberger Company</a></td>
      <td>The Longaberger Company is an American manufacturer and distributor of handcrafted maple wood baskets and other home and lifestyle products. The company opened in 1973, was acquired in 2013 by CVSL, Inc., and closed in 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Controlled_clinical_trials">Controlled clinical trials</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration_with_the_Axis_powers">Collaboration with the Axis powers</a></td>
      <td>Within nations occupied by the Axis powers in World War II, some citizens and organizations, prompted by nationalism, ethnic hatred, anti-communism, antisemitism, opportunism, self-defense, or often a combination, knowingly collaborated with the Axis Powers. Some of these collaborators committed war crimes, crimes against humanity, or atrocities in the Holocaust.Collaboration has been defined as cooperation between elements of the population of a defeated state and representatives of the victorious power.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Document_collaboration">Document collaboration</a></td>
      <td>Document and file collaboration are the tools or systems set up to help multiple people work together on a single document or file to achieve a single final version. Normally, this is software that allows teams to work on a single document, such as a word processor document, at the same time from different computer terminals or mobile devices.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>NEUROGEN CORP      ITEM 1A RISK FACTORS           The following information <font color="blue">sets forth risk factors</font> that could cause the     Company’s  actual results to <font color="blue">differ <font color="blue">materially</font> from</font> those contained in     forward-looking statements that have been made in this <font color="blue">Annual Report </font>on <font color="blue">Form     </font>10-K and those that may be made from time to time</td>
    </tr>
    <tr>
      <td>If any of the risks     actually occur, the Company’s business, results of operation, prospects or     <font color="blue"><font color="blue">financial condition</font> could</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks not <font color="blue">presently known</font> or that the     Company currently deems <font color="blue">immaterial may also affect</font> business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">testing process</font> for the Company’s <font color="blue"><font color="blue">drug candidate</font>s</font> is long, costly, and     uncertain, and most <font color="blue"><font color="blue">drug candidate</font>s</font> do not get approved</td>
    </tr>
    <tr>
      <td>Even if approved     for use in humans, the Company’s <font color="blue"><font color="blue">drug candidate</font>s</font> may later prove to be     unsafe or <font color="blue">in<font color="blue">effective</font></font></td>
    </tr>
    <tr>
      <td>The  Company’s  potential  drug  candidates  <font color="blue">must go through</font> extensive     preclinical (animal) and clinical (human) trials to prove that the drug is     safe and <font color="blue">effective</font> before it can be <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>This extensive testing     takes <font color="blue">several years</font>, is <font color="blue">quite expensive</font>, and more often than not leads to     the <font color="blue">conclusion</font> that a <font color="blue">drug candidate</font> is not suitable for <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>A very       ______________________________________________________________________       Page 14       <font color="blue"><font color="blue">significant</font> majority</font> (estimated to be <font color="blue">greater than</font> 80 to 90 percent) of all     drugs  which  <font color="blue">enter human <font color="blue"><font color="blue">clinical trial</font>s</font> fail</font> to reach the market</td>
    </tr>
    <tr>
      <td>In     addition, the risk of failure is the highest when working <font color="blue">on drug targets</font>     that have not <font color="blue">yet been validated by</font> the successful <font color="blue">commercialization</font> of a     prior drug</td>
    </tr>
    <tr>
      <td>Moreover, even if <font color="blue">early drug testing</font> appears positive, later     testing or even the results of usage after <font color="blue">commercialization</font> may preclude     <font color="blue">further use</font> of a drug</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">current <font color="blue">regulatory</font> framework could</font>     change,  or <font color="blue">additional regulations could</font> arise at any <font color="blue">stage during</font> our     <font color="blue">product <font color="blue">development</font></font> or marketing, which may affect its ability to obtain or     maintain approval of its products or require Neurogen to make <font color="blue">significant</font>     <font color="blue"><font color="blue">expenditure</font>s</font> to obtain or maintain such approvals</td>
    </tr>
    <tr>
      <td>The  results  of <font color="blue">preclinical tests</font> performed on animals are not always     accurate <font color="blue">predictors</font> of the safety, <font color="blue">effective</font>ness, or <font color="blue">suitability</font> of drugs in     humans</td>
    </tr>
    <tr>
      <td>Similarly, the results of initial <font color="blue"><font color="blue">clinical trial</font>s</font> do not <font color="blue">necessarily</font>     <font color="blue">accurately</font> predict the results that will be obtained in the <font color="blue">later stages</font> of     clinical  trials</td>
    </tr>
    <tr>
      <td>The  appearance of adverse side effects, inadequate     <font color="blue">therapeutic</font> efficacy or inadequate <font color="blue">drug properties could prevent</font> or slow     <font color="blue">product <font color="blue">development</font></font> efforts at any stage of <font color="blue">product <font color="blue">development</font></font> by delaying     or preventing <font color="blue"><font color="blue">clinical trial</font>s</font>, delaying or <font color="blue">preventing <font color="blue">regulatory</font> approval by</font>     the  FDA  or foreign <font color="blue">regulatory</font> <font color="blue">authorities</font> or <font color="blue">adversely</font> <font color="blue">affecting</font> the     commercial potential of a <font color="blue">drug candidate</font></td>
    </tr>
    <tr>
      <td><font color="blue">Either the FDA or <font color="blue">the Company </font></font>may     <font color="blue">suspend <font color="blue"><font color="blue">clinical trial</font>s</font> at</font> any time if the FDA or it believes that the     <font color="blue">individuals</font> <font color="blue">participating</font> in the trials are being exposed to unacceptable     health  risks</td>
    </tr>
    <tr>
      <td>Even <font color="blue">products approved by</font> the FDA or foreign <font color="blue">regulatory</font>     <font color="blue">authorities</font>  may later exhibit adverse side effects that prevent their     widespread use or <font color="blue">necessitate</font> their withdrawal from the market</td>
    </tr>
    <tr>
      <td>As a result,     the Company’s <font color="blue"><font color="blue">drug candidate</font>s</font> may prove to be unsafe or <font color="blue">in<font color="blue">effective</font></font> in     humans, produce undesirable side effects, or fail to get through the testing     phases to <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to <font color="blue">strict <font color="blue">governmental regulation</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">If <font color="blue">the Company </font>    </font>cannot  obtain  product  approvals or if it <font color="blue">cannot <font color="blue">comply with</font> ongoing</font>     <font color="blue"><font color="blue">governmental regulation</font>s</font>, its business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The Company’s products are subject to extensive regulation and review by     <font color="blue">numerous federal</font>, state and <font color="blue">local government agencies both</font> in the United     States  and in other countries where it intends to test and market its     products</td>
    </tr>
    <tr>
      <td>The <font color="blue">process by which</font> <font color="blue">the Company </font>obtains <font color="blue">regulatory</font> approval to     market a <font color="blue">product involves</font> substantial cost and can take many years</td>
    </tr>
    <tr>
      <td>The data     <font color="blue">the Company </font>obtains <font color="blue">from preclinical</font> and <font color="blue"><font color="blue"><font color="blue">clinical trial</font>s</font> may</font> be subject to     <font color="blue">varying interpretations which</font> can delay, limit or prevent the approval of     the  <font color="blue">relevant governmental authority</font></td>
    </tr>
    <tr>
      <td>If there are delays and costs in     obtaining <font color="blue">regulatory</font> approvals, the Company’s <font color="blue">product <font color="blue">development</font></font> efforts     and <font color="blue">consequently</font> its business could be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Agencies, such as     the FDA, may change their view of acceptable <font color="blue">endpoints</font> for <font color="blue"><font color="blue">clinical trial</font>s</font>     once  they have begun, clinical data may not be <font color="blue">accepted by</font> the FDA or     similar agencies, or approvals may not be granted on a timely basis, if at     all</td>
    </tr>
    <tr>
      <td>Even if <font color="blue">the Company </font>obtains <font color="blue">regulatory</font> approval of a drug, the approval     may include <font color="blue">limitations</font> and <font color="blue"><font color="blue">restrictions</font> on</font> the drug’s use</td>
    </tr>
    <tr>
      <td>In addition, the     Company’s  products are subject to continual <font color="blue">regulatory</font> review and any     <font color="blue">subsequent discovery</font> of <font color="blue">previously unrecognized problems could</font> result in     <font color="blue">restrictions</font> being <font color="blue">placed on either</font> <font color="blue">the Company </font>or its products</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">restrictions</font> could include an order to withdraw a <font color="blue">product from</font> the market</td>
    </tr>
    <tr>
      <td>The failure to <font color="blue">comply with</font> applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> can, among     other things, result in fines, suspension of <font color="blue">regulatory</font> approvals, product     recalls,  seizure  of  products,  operating  <font color="blue">restrictions</font> and criminal     <font color="blue">prosecution</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">faces vigorous competition</font> in the areas of <font color="blue">drug discovery</font> and     <font color="blue">development</font>,  which may result in others developing or <font color="blue">commercializing</font>     products before or more <font color="blue"><font color="blue">successfully</font> than</font> it does</td>
    </tr>
    <tr>
      <td>______________________________________________________________________       Page 15       The <font color="blue"><font color="blue">pharmaceutical</font> industry</font> is <font color="blue">highly <font color="blue">competitive</font></font> and is <font color="blue">affected by new</font>     <font color="blue">technologies</font>, <font color="blue"><font color="blue">governmental regulation</font>s</font>, healthcare legislation, <font color="blue">availability</font>     of financing, <font color="blue">litigation</font> and other factors</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">cannot assure</font> the     reader that its <font color="blue"><font color="blue"><font color="blue">competitor</font>s</font> will</font> not succeed in developing <font color="blue">technologies</font>     (including <font color="blue">drug discovery</font> techniques) and products that are more <font color="blue">effective</font>     than its own or that are <font color="blue"><font color="blue">commercialize</font>d</font> prior to similar <font color="blue">technologies</font> or     products of its own</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">development</font>s by <font color="blue">others may</font> render its     products under <font color="blue">development</font> or its <font color="blue">technologies</font> non<font color="blue">competitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>If the Company’s <font color="blue">product candidates</font> receive FDA approval, they <font color="blue">will compete</font>     with  a  number  of existing and <font color="blue">future drugs</font> and therapies developed,     <font color="blue"><font color="blue">manufacture</font>d</font> and <font color="blue">marketed by others</font></td>
    </tr>
    <tr>
      <td>Existing or future <font color="blue">competing product</font>s     may provide greater <font color="blue">therapeutic</font> convenience or clinical or other benefits     for  a  <font color="blue">specific indication than</font> its products, or <font color="blue">may offer comparable</font>     <font color="blue">performance at lower costs</font></td>
    </tr>
    <tr>
      <td>If the Company’s products are unable to capture     or maintain market share, it will not achieve <font color="blue">significant</font> <font color="blue">product revenues</font>     and its <font color="blue"><font color="blue">financial condition</font> will</font> be <font color="blue">materially</font> <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>competes against fully integrated <font color="blue"><font color="blue">pharmaceutical</font> companies</font> or     other companies that <font color="blue"><font color="blue">collaborate</font> with larger <font color="blue"><font color="blue">pharmaceutical</font> companies</font></font>,     academic <font color="blue">institutions</font>, government agencies and other public and private     <font color="blue">research <font color="blue">organizations</font></font></td>
    </tr>
    <tr>
      <td>Many of these <font color="blue"><font color="blue">competitor</font>s</font> have products already     approved,  marketed  or  in  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In  addition, many of these     <font color="blue"><font color="blue">competitor</font>s</font>, either alone or <font color="blue">together with</font> their <font color="blue"><font color="blue">collaborative</font> partners</font>,     operate <font color="blue">larger research</font> and <font color="blue">development</font> programs, have <font color="blue"><font color="blue">substantially</font> greater</font>     <font color="blue">financial resources</font>, experience in developing products, obtaining FDA and     other  <font color="blue">regulatory</font>  approvals, <font color="blue">formulating</font> and <font color="blue">manufacturing</font> drugs, and     <font color="blue">commercializing</font> drugs than <font color="blue">the Company </font>does</td>
    </tr>
    <tr>
      <td>If a <font color="blue">competitor</font> were to develop     and <font color="blue">successfully</font> <font color="blue">commercialize</font> a drug before a similar one that <font color="blue">the Company </font>    was  working on, it would put <font color="blue">the Company </font>at a <font color="blue">significant</font> <font color="blue">competitive</font>     <font color="blue">disadvantage</font></td>
    </tr>
    <tr>
      <td>The  Company has limited experience in the <font color="blue">clinical process</font> and relies     <font color="blue">heavily on</font> its <font color="blue"><font color="blue">collaborative</font> partners</font> for research and <font color="blue">development</font> funding     and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has <font color="blue">depended on</font> its <font color="blue"><font color="blue">collaborative</font> partners</font> to fund a <font color="blue">significant</font>     portion of its research and <font color="blue">development</font> expenses and to <font color="blue">manufacture</font> and     market any products that might result from its <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>In the fiscal     years ended <font color="blue">December </font>31, 2005, 2004, and 2003, <font color="blue">the Company </font>incurred dlra38dtta5     million,  dlra31dtta3 million, and dlra32dtta2 million in research and <font color="blue">development</font>     expenses (including <font color="blue">stock compensation expense</font> of dlra0dtta5 million, dlra0dtta4 million     and dlra0dtta3 million respectively) and recognized dlra3dtta9 million, dlra10dtta3 million,     and dlra4dtta8 million respectively, in research and <font color="blue">development</font> revenue from     <font color="blue">corporate partners</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">the Company </font>has limited experience conducting     <font color="blue"><font color="blue">clinical trial</font>s</font>, it often <font color="blue">depends on</font> its <font color="blue"><font color="blue">collaborative</font> partners</font> with respect     to <font color="blue">regulatory</font> filings relating to, and the <font color="blue">clinical testing</font> of, compounds     developed under its <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>In particular, <font color="blue">the Company </font><font color="blue">depends on</font>     Merck  to  conduct <font color="blue"><font color="blue">clinical trial</font>s</font> for compounds on which it <font color="blue">and <font color="blue">Merck     </font></font><font color="blue">collaborate</font> in our VR1 program</td>
    </tr>
    <tr>
      <td>The Company’s reliance on <font color="blue"><font color="blue">collaborative</font> partners</font>, whose interests may not     coincide  with  its interests, exposes it to many risks, including the     following:       ·     that a <font color="blue">collaborator will</font> halt, delay, or repeat <font color="blue"><font color="blue">clinical trial</font>s</font>;           ·     that a <font color="blue">collaborator will</font> alter the amount or timing of <font color="blue">resources dedicated</font>     to the Company’s <font color="blue">collaboration</font>;       ______________________________________________________________________       Page 16       ·     that a <font color="blue">collaborator will</font> dispute the Company’s <font color="blue">rights under</font> an <font color="blue">agreement</font>;       ·     that a <font color="blue">collaborator will</font> attempt to <font color="blue">independently</font> develop a <font color="blue">competing drug</font>     on its own or in <font color="blue">conjunction with</font> a <font color="blue">third party</font>;       ·     that existing <font color="blue">collaboration</font> <font color="blue">agreement</font>s will not be extended;       ·     that a <font color="blue">collaborator will</font> not continue to develop a <font color="blue">drug candidate</font> after a     <font color="blue">collaboration</font> <font color="blue">agreement</font> has ended; and       ·     that a <font color="blue">collaborator will</font> breach or terminate an <font color="blue">agreement</font> with the Company</td>
    </tr>
    <tr>
      <td>If any of these risks were to occur, the <font color="blue">research program</font> in question, and     possibly the Company’s business, would be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The Company’s     existing <font color="blue">collaboration</font> with Merck may be <font color="blue">unsuccessful</font> and it may not receive     any  <font color="blue">future milestone payments</font> or royalties</td>
    </tr>
    <tr>
      <td>If the Company’s existing     <font color="blue">collaboration</font> is not continued or is <font color="blue">unsuccessful</font>, its <font color="blue">product <font color="blue">development</font></font>     efforts and <font color="blue">consequently</font> business would be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Delays or     <font color="blue">discontinuation</font> of its <font color="blue">collaborative</font> programs could <font color="blue">significant</font>ly delay and     decrease the <font color="blue">probability</font> of <font color="blue">the Company </font>ever achieving <font color="blue">product revenues</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could negatively impact</font> its ability to <font color="blue">access capital</font> and the cost of     capital</td>
    </tr>
    <tr>
      <td>If the Company’s <font color="blue">collaborative</font> partner Merck does not continue the     <font color="blue">development</font> of its <font color="blue">compounds under</font> our VR1 <font color="blue"><font color="blue">collaboration</font>s</font>, it may not be     able to do so on its own</td>
    </tr>
    <tr>
      <td>The Company’s current <font color="blue">collaboration</font>, with Merck,     is  subject  to <font color="blue">certain diligence <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>Merck has the right to     determine when and if to <font color="blue">advance compounds</font> in the <font color="blue">clinical process</font></td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">the Company </font>may not be able to <font color="blue">find suitable partners</font> for any new     <font color="blue"><font color="blue">collaboration</font>s</font> it may seek to enter</td>
    </tr>
    <tr>
      <td>Any new <font color="blue"><font color="blue">collaboration</font>s</font> would likely be     subject  to  some  or  all of the <font color="blue">same risks as</font> the Company’s existing     <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>A  consequence of entering into <font color="blue">collaborative</font> <font color="blue">arrangements</font> is that the     Company’s <font color="blue">potential upside</font> is smaller if a <font color="blue">successful product emerges than</font>     if it <font color="blue">successfully</font> <font color="blue"><font color="blue">commercialize</font>d</font> a <font color="blue">product on</font> its own</td>
    </tr>
    <tr>
      <td>Historically, <font color="blue">the Company </font>has entered into strategic <font color="blue"><font color="blue">collaboration</font>s</font> with     large <font color="blue"><font color="blue">pharmaceutical</font> companies</font> to develop and <font color="blue">commercialize</font> new drugs</td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font>its <font color="blue">collaboration</font> with Merck, <font color="blue">the Company </font>has granted Merck the exclusive     worldwide license to <font color="blue">manufacture</font>, use and sell products developed under the     Merck <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>While these <font color="blue"><font color="blue">collaboration</font>s</font> have allowed <font color="blue">the Company </font>to     recoup its research and <font color="blue">development</font> expenses and avoid risking its own     capital on these <font color="blue">activities</font>, they have, in most cases, limited its upside to     receiving only royalties based on net sales levels should a successful drug     result</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue"><font color="blue">periodically explores</font> new alliances</font> that <font color="blue">may never materialize</font>     or may fail</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">periodically explores</font> a variety of <font color="blue">possible <font color="blue">partnership</font>s</font> or     alliances in an effort to <font color="blue">gain access</font> to <font color="blue">additional complimentary resources</font></td>
    </tr>
    <tr>
      <td>At the current time, <font color="blue">the Company </font><font color="blue">cannot predict</font> what form such a <font color="blue">partnership</font>     or <font color="blue">alliance might</font> take</td>
    </tr>
    <tr>
      <td>Such strategic business <font color="blue">alliances could</font> result in:     the issuance of <font color="blue">equity securities</font> that would dilute <font color="blue">stockholders</font>’ percentage     ownership;  the <font color="blue">expenditure</font> of substantial operational, financial, and     <font color="blue">management</font>  resources in integrating new businesses, <font color="blue">technologies</font>, and     products; the <font color="blue">assumption</font> of substantial actual or <font color="blue">contingent liabilities</font>; or     a business <font color="blue">combination transaction</font> featuring terms that <font color="blue"><font color="blue">stockholders</font> might</font>     not deem desirable</td>
    </tr>
    <tr>
      <td>______________________________________________________________________       Page 17       There have been a <font color="blue">significant</font> number of recent business <font color="blue">combinations among</font>     large <font color="blue"><font color="blue">pharmaceutical</font> companies</font> that have resulted in a reduced number of     <font color="blue">potential future corporate <font color="blue">collaborators</font></font></td>
    </tr>
    <tr>
      <td>If business <font color="blue">combinations involving</font>     the Company’s corporate <font color="blue">collaborators</font> were to occur, the effect could be to     diminish,  terminate  or  cause delays in one or more of its corporate     <font color="blue"><font color="blue">collaboration</font>s</font></td>
    </tr>
    <tr>
      <td>Developing the Company’s <font color="blue"><font color="blue">drug candidate</font>s</font>, particularly its unpartnered     <font color="blue">product candidates</font>, will require <font color="blue">significant</font> additional <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>The     Company  is  not <font color="blue">certain how</font> much capital it may need, and it may have     <font color="blue"><font color="blue">difficult</font>y raising</font> needed capital in the future on favorable terms or at     all</td>
    </tr>
    <tr>
      <td>The  Company has spent and <font color="blue">will continue</font> to spend substantial funds to     complete the research, <font color="blue">development</font> and <font color="blue">clinical testing</font> of its products</td>
    </tr>
    <tr>
      <td>In     the future <font color="blue">the Company </font>expects to need <font color="blue">additional funds</font> for these purposes     and to <font color="blue">establish additional clinical</font>- and commercial-scale <font color="blue">manufacturing</font>     <font color="blue">arrangements</font>  and to provide for the marketing and <font color="blue">distribution</font> of its     products</td>
    </tr>
    <tr>
      <td>The  Company may not be able to acquire <font color="blue">additional funds</font> on     <font color="blue">commercially reasonable terms</font> or at all</td>
    </tr>
    <tr>
      <td>In particular, the process of     carrying out the <font color="blue">development</font> of its own unpartnered <font color="blue">product candidates</font> to     <font color="blue">later stages</font> of <font color="blue">development</font> and developing other <font color="blue">research program</font>s to the     stage  that they may be partnered, if at all, will require <font color="blue">significant</font>     additional <font color="blue"><font color="blue">expenditure</font>s</font>, including the <font color="blue">expenses associated with preclinical</font>     testing, <font color="blue"><font color="blue">clinical trial</font>s</font> and other <font color="blue">product <font color="blue">development</font></font> activites</td>
    </tr>
    <tr>
      <td>If the     Company cannot acquire <font color="blue">adequate funds</font>, it may have to delay, reduce the     scope of or <font color="blue">eliminate one</font> or more of its research or <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>Such a reduction could <font color="blue">concentrate</font> its risks in fewer programs</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">capital <font color="blue">requirements</font> will depend on</font> many factors, including:       ·     continued progress of its research and <font color="blue">development</font> programs;       ·     the Company’s ability to market and distribute any products it develops and     to establish new <font color="blue">collaborative</font> and licensing <font color="blue">arrangements</font>;       ·     changes in its existing <font color="blue">collaborative</font> relationships;       ·     progress <font color="blue">with pre<font color="blue">clinical studies</font></font> and <font color="blue"><font color="blue">clinical trial</font>s</font>;       ·     the time and <font color="blue">costs involved</font> in pursuing <font color="blue">regulatory</font> clearance;       ·     the <font color="blue">costs involved</font> in preparing, filing, prosecuting, maintaining and     <font color="blue">enforcing patent</font> claims; and       ·     <font color="blue">competing <font color="blue">technological</font></font> and market <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>______________________________________________________________________           Page 18       <font color="blue">The Company </font>may seek to raise any <font color="blue">necessary</font> <font color="blue">additional funds</font> through equity     or debt financings, <font color="blue">collaborative</font> <font color="blue">arrangements</font> with <font color="blue">corporate partners</font> or     other <font color="blue">sources which may dilute</font> the interest its <font color="blue">existing <font color="blue">stockholders</font></font> have     in  its  company</td>
    </tr>
    <tr>
      <td>In  addition, in the event that <font color="blue">the Company </font>obtains     <font color="blue">additional funds</font> through <font color="blue">arrangements</font> with <font color="blue"><font color="blue">collaborative</font> partners</font> or other     sources, these <font color="blue">arrangements</font> may require it to <font color="blue">give up rights</font> to some of its     <font color="blue">technologies</font>, <font color="blue">product candidates</font> or products under <font color="blue">development</font> that it would     <font color="blue">otherwise seek</font> to develop or <font color="blue">commercialize</font> ourselves</td>
    </tr>
    <tr>
      <td>The Company’s patents, <font color="blue">trade secrets</font> and <font color="blue">confidentiality</font> <font color="blue">agreement</font>s with     <font color="blue">collaborators</font>, employees and <font color="blue">others may</font> be invalidated or inadequate to     protect its <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">the Company </font>or its <font color="blue">collaborators</font> are unable to <font color="blue">adequately</font> protect or     enforce  our  <font color="blue"><font color="blue">intellectual</font> property</font>, its <font color="blue">competitive</font> position could be     impaired</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">success depends</font> in part on its ability to obtain     patents,  maintain <font color="blue">trade secrets</font> and operate <font color="blue">without infringing on</font> the     <font color="blue"><font color="blue">intellectual</font> property</font> rights of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">files patent</font>     <font color="blue">applications both</font> in the <font color="blue">United States </font>and in <font color="blue">foreign countries</font> to protect     both its products and its processes</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of <font color="blue">biotechnology</font>     and <font color="blue"><font color="blue">pharmaceutical</font> firms</font> is <font color="blue">highly uncertain</font> and involves many <font color="blue">complex legal</font>     and  technical  issues</td>
    </tr>
    <tr>
      <td>The  Company’s <font color="blue">patent applications may</font> not be     successful or its current or <font color="blue">future patents may</font> not afford <font color="blue">the Company </font>    protection  against its <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>It is possible that the Company’s     <font color="blue">patents will</font> be <font color="blue">successfully</font> challenged or that <font color="blue">patents issued</font> to <font color="blue">others may</font>     preclude it from <font color="blue">commercializing</font> its products</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>to establish the     validity of patents, to defend against <font color="blue">infringement</font> claims or to assert     <font color="blue">infringement</font> claims <font color="blue">against others</font> can be lengthy and expensive</td>
    </tr>
    <tr>
      <td>Moreover,     much of the Company’s expertise and <font color="blue">technology cannot</font> be patented or, if     patented, any <font color="blue">infringement</font> cannot be <font color="blue">readily monitored</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>also     relies <font color="blue">heavily on</font> <font color="blue">trade secrets</font> (for example, its AIDD^TM system is not     patented, but its <font color="blue">proprietary elements</font> are protected as <font color="blue">trade secrets</font>) and     <font color="blue">confidentiality</font>  <font color="blue">agreement</font>s  with  <font color="blue">collaborators</font>, advisors, employees,     consultants, vendors and other <font color="blue">service providers</font></td>
    </tr>
    <tr>
      <td>It is possible that these     <font color="blue">agreement</font>s may be breached or that the Company’s <font color="blue">trade secrets</font> may otherwise     <font color="blue">become known</font> or be <font color="blue">independently</font> discovered by <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>The Company’s     <font color="blue">product <font color="blue">development</font></font> efforts and <font color="blue">consequently</font> its business would be <font color="blue">adversely</font>     affected if its <font color="blue"><font color="blue">competitor</font>s</font> were able to learn its secrets or if it was     unable to protect its <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is subject to <font color="blue">uncertainties</font> regarding <font color="blue">healthcare <font color="blue">reimbursement</font></font>     and reform</td>
    </tr>
    <tr>
      <td>In the event that it is successful in bringing any products to     market,  its  revenues may be <font color="blue"><font color="blue">adversely</font> affected</font> if it fails to obtain     acceptable prices or adequate <font color="blue">reimbursement</font> for the cost of its products     from third-party payors</td>
    </tr>
    <tr>
      <td>The  <font color="blue">continuing efforts</font> of the government, insurance companies, health     <font color="blue">maintenance <font color="blue">organizations</font></font> and other payers of <font color="blue">healthcare costs</font> to contain or     <font color="blue">reduce costs</font> of <font color="blue">healthcare may affect</font> the Company’s <font color="blue">future revenues</font> and     <font color="blue">profitability</font>,  the <font color="blue">future revenues</font> and <font color="blue">profitability</font> of its potential     customers, suppliers and <font color="blue"><font color="blue">collaborative</font> partners</font>, and the <font color="blue">availability</font> of     capital</td>
    </tr>
    <tr>
      <td>For example, in certain foreign markets, pricing or <font color="blue">profitability</font>     of <font color="blue">prescription <font color="blue">pharmaceutical</font>s</font> is subject to <font color="blue">government control</font></td>
    </tr>
    <tr>
      <td>In the     United States, both the federal and state <font color="blue">governments will likely continue</font>     to <font color="blue">focus on healthcare reform</font>, the cost of <font color="blue">prescription <font color="blue">pharmaceutical</font>s</font> and     reform  of the <font color="blue">Medicare and Medicaid </font>systems</td>
    </tr>
    <tr>
      <td>While <font color="blue">the Company </font>cannot     <font color="blue">predict whether</font> any <font color="blue">such proposals will</font> be adopted, the <font color="blue">announcement</font> or     adoption of such proposals <font color="blue">could negatively impact</font> its business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Company’s ability to market its products <font color="blue">successfully</font> will depend, in     part, on the extent to which <font color="blue">appropriate</font> <font color="blue">reimbursement</font>s for the cost of its     products and related <font color="blue">treatments</font> are available from governmental <font color="blue">authorities</font>,     <font color="blue">private health insurers</font> and other <font color="blue">organizations</font>, such as HMOs</td>
    </tr>
    <tr>
      <td><font color="blue">Significant     </font><font color="blue">uncertainty</font>  exists  as  to the <font color="blue">reimbursement</font> status of <font color="blue">newly approved</font>     <font color="blue">healthcare products</font></td>
    </tr>
    <tr>
      <td>Third-party payors, including Medicare, are <font color="blue">constantly</font>     <font color="blue">challenging</font>  the  <font color="blue">prices charged</font> for <font color="blue">medical products</font> and services</td>
    </tr>
    <tr>
      <td>If     third-party payors institute cost containment measures or fail to approve     the Company’s products for <font color="blue">reimbursement</font>, its <font color="blue">future sales may</font> be <font color="blue">adversely</font>     affected, as patients will opt for a <font color="blue">competing product</font> that is approved for     <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>______________________________________________________________________       Page 19       <font color="blue">The Company </font>may be unable to attract and retain qualified <font color="blue">management</font> and     <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>The  success  of the Company’s business depends, in large part, on its     <font color="blue">continued ability</font> to attract and retain highly qualified <font color="blue">management</font> and     <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>faces <font color="blue">significant</font> competition for such     <font color="blue">individuals</font>  from  other  companies,  academic  <font color="blue">institutions</font> and other     <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>In particular, there is currently a shortage of qualified     Ph</td>
    </tr>
    <tr>
      <td>D chemists and <font color="blue">drug metabolism scientists</font> in the industry</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>    <font color="blue">cannot assure</font> the reader that it will be able to attract or retain qualified     personnel or that the costs of retaining <font color="blue">such personnel will</font> not <font color="blue">materially</font>     increase</td>
    </tr>
    <tr>
      <td>The  failure  to attract and retain these <font color="blue">key personnel</font> and     <font color="blue">management</font> staff, or the loss of any of the Company’s current <font color="blue">management</font>     team and its <font color="blue">inability replace such staff on</font> a <font color="blue">timely basis could</font> <font color="blue">adversely</font>     affect its business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>relies upon <font color="blue">third parties</font> for its <font color="blue">manufacturing</font> <font color="blue">requirements</font>,     and it <font color="blue">cannot assure</font> the reader that it will be able to <font color="blue">manufacture</font> products     on a timely and <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td>To complete its <font color="blue"><font color="blue">clinical trial</font>s</font> and to <font color="blue">commercialize</font> its <font color="blue">product candidates</font>,     <font color="blue">the Company </font>needs access to, or <font color="blue">development</font> of, <font color="blue">facilities</font> to <font color="blue">manufacture</font> a     sufficient  supply  of its <font color="blue">product candidates</font></td>
    </tr>
    <tr>
      <td>Neurogen <font color="blue">depends on</font> its     <font color="blue">collaborators</font>  or  third  parties for the <font color="blue">manufacture</font> of compounds for     pre-clinical,  clinical  and <font color="blue">commercial purposes</font> in their FDA-approved     <font color="blue">manufacturing</font> <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>The Company’s products may be in <font color="blue">competition with</font>     other products for access to these <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Consequently, its products     may  be  subject  to  <font color="blue">manufacturing</font> delays if <font color="blue">collaborators</font> or outside     <font color="blue">contractors give</font> other <font color="blue">products greater priority than</font> its products</td>
    </tr>
    <tr>
      <td>For this     and other reasons, the Company’s <font color="blue">collaborators</font> or <font color="blue">third parties</font> may not be     able to <font color="blue">manufacture</font> these products in a cost-<font color="blue">effective</font> or <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>If     not performed in a <font color="blue">timely manner</font>, the <font color="blue">clinical trial</font> <font color="blue">development</font> of its     <font color="blue">product candidates</font> or their submission for <font color="blue">regulatory</font> approval could be     delayed, and its ability to deliver <font color="blue">products on</font> a <font color="blue">timely basis could</font> be     impaired or precluded</td>
    </tr>
    <tr>
      <td>Neurogen may not be able to <font color="blue">enter into</font> any <font color="blue">necessary</font>     third-party <font color="blue">manufacturing</font> <font color="blue">arrangements</font> on acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>The     Company does not intend to develop or acquire <font color="blue">facilities</font> for the <font color="blue">manufacture</font>     of <font color="blue">product candidates</font> for <font color="blue"><font color="blue">clinical trial</font>s</font> or <font color="blue">commercial purposes</font> in the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In our ongoing <font color="blue">collaboration</font>, Merck is responsible for     <font color="blue">manufacturing</font>   or  obtaining  clinical  and  commercial  supplies  of     <font color="blue">pharmaceutical</font>  compounds</td>
    </tr>
    <tr>
      <td>In our <font color="blue">unpartnered program</font> we <font color="blue">utilize third</font>     parties  to  prepare and formulate <font color="blue">pharmaceutical</font> compounds for use in     <font color="blue">clinical studies</font></td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">current dependence upon others</font> for the     <font color="blue">manufacture</font> of its <font color="blue">products may reduce</font> its <font color="blue">future profit margin</font> and limit     its ability to <font color="blue">commercialize</font> <font color="blue">products on</font> a timely and <font color="blue">competitive</font> basis</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font><font color="blue">lacks marketing</font> and sales experience</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>currently has no marketing, sales or <font color="blue">distribution</font> efforts and,     currently, <font color="blue">the Company </font>intends to <font color="blue">rely primarily on existing</font> or future     <font color="blue">collaborative</font>  partners  for  this expertise if one of its products is     <font color="blue">successfully</font> <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>Therefore, to service markets for any areas in     which it has retained sales and <font color="blue">marketing rights</font> or in the event that any of     its <font color="blue">collaborative</font> <font color="blue">agreement</font>s is terminated, <font color="blue">the Company </font>must develop a sales     <font color="blue">force with technical expertise</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has no experience in developing,     training or managing a sales       force  and  <font color="blue">would incur</font> substantial <font color="blue">additional expenses</font> in developing,     training and <font color="blue">managing such</font> a <font color="blue">sales force</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>may be unable to build     such a <font color="blue">sales force</font>, the cost of <font color="blue">establishing such</font> a <font color="blue">sales force</font> may exceed     any <font color="blue">product revenues</font>, or its <font color="blue">direct marketing</font> and <font color="blue">sales efforts may</font> be     <font color="blue">unsuccessful</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">the Company </font><font color="blue">competes with</font> many other companies     that  currently  have  extensive  and  well-funded marketing and sales     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The Company’s marketing and <font color="blue">sales efforts may</font> be unable to     compete <font color="blue">successfully</font> against such other companies</td>
    </tr>
    <tr>
      <td>Moreover, even if the     Company or one of its partners is able to bring a product to market, it is     possible that these products will not gain <font color="blue">acceptance</font> among physicians,     patients or third-party payors</td>
    </tr>
    <tr>
      <td>______________________________________________________________________       Page 20       The Company’s business exposes it to <font color="blue">clinical trial</font> and <font color="blue">product <font color="blue">liability</font></font>     claims</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>faces an inherent risk of exposure to <font color="blue">product <font color="blue">liability</font></font> claims     in the event that the use of one of its products is alleged to have caused     an adverse if any effect on patients</td>
    </tr>
    <tr>
      <td>This risk exists for products being     tested in human <font color="blue"><font color="blue">clinical trial</font>s</font>, as well as products that receive <font color="blue">regulatory</font>     approval for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>of <font color="blue">pharmaceutical</font>s have been the     subject of <font color="blue">significant</font> <font color="blue">product <font color="blue">liability</font></font> <font color="blue">litigation</font>, <font color="blue">and Neurogen </font>cannot     assure the reader that it will not be <font color="blue">threatened with</font> or become subject to     such a claim</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>maintains limited <font color="blue">product <font color="blue">liability</font></font> insurance for     compounds it is testing in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>It currently maintains <font color="blue">liability</font>     insurance  of dlra5dtta0 million in coverage for the <font color="blue"><font color="blue">clinical trial</font>s</font> that it     conducts</td>
    </tr>
    <tr>
      <td>The  Company’s <font color="blue">partners indemnify</font> the Company, <font color="blue">with certain</font>     <font color="blue">exceptions</font>, for <font color="blue">collaborative</font> compounds they are testing in <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>intends to seek additional <font color="blue">product <font color="blue">liability</font></font> <font color="blue">insurance coverage</font>     if and when its products are <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>It may not, however, be able to     obtain <font color="blue">such insurance at</font> acceptable costs, if at all, or <font color="blue">such coverage</font>, if     obtained, may not be adequate to cover any claims</td>
    </tr>
    <tr>
      <td>If <font color="blue">the Company </font>cannot     obtain <font color="blue">sufficient <font color="blue">insurance coverage</font> at</font> an acceptable cost or otherwise     protect against potential <font color="blue">product <font color="blue">liability</font></font> claims it could be prevented     from  <font color="blue">commercializing</font> our products</td>
    </tr>
    <tr>
      <td>Or, if <font color="blue">the Company </font>is subject to a     product  <font color="blue">liability</font>  claim  where claims or <font color="blue">losses exceed</font> its <font color="blue">liability</font>     <font color="blue">insurance coverage</font> and its ability to pay, it <font color="blue">may go out</font> of business</td>
    </tr>
    <tr>
      <td>The  Company’s  business  <font color="blue">involves <font color="blue">hazardous</font> materials</font> and the risk of     <font color="blue">environmental</font> <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">connection with</font> its research and <font color="blue">development</font> <font color="blue">activities</font>, <font color="blue">the Company </font>is     subject to federal, state and local laws, rules, regulations and policies     governing the use, generation, <font color="blue">manufacture</font>, storage, air emission, effluent     discharge, handling and disposal of certain materials, biological specimens     and wastes</td>
    </tr>
    <tr>
      <td>Although <font color="blue">the Company </font>believes that it has <font color="blue">complied with</font> the     applicable laws, regulations and policies in all material respects and have     not been required to correct any <font color="blue">noncompliance which</font> is material to its     business,  it  may  have  to  incur  <font color="blue">significant</font>  costs to <font color="blue">comply with</font>     <font color="blue">environmental</font>  and  health  and  <font color="blue">safety regulations</font> in the future</td>
    </tr>
    <tr>
      <td>The     Company’s research and <font color="blue">development</font> involves the <font color="blue">controlled use</font> of <font color="blue">hazardous</font>     materials, including but not limited to certain <font color="blue">hazardous</font> chemicals and     <font color="blue">radioactive materials</font></td>
    </tr>
    <tr>
      <td>Although it believes that its <font color="blue">safety procedures</font> for     handling  and  disposing  of  such materials <font color="blue">comply with</font> the standards     <font color="blue">prescribed by</font> state and <font color="blue">federal regulations</font>, <font color="blue">the Company </font><font color="blue">cannot completely</font>     eliminate  the  risk  of <font color="blue">accidental contamination</font> or <font color="blue">injury from</font> these     materials</td>
    </tr>
    <tr>
      <td>In the event of such an occurrence, <font color="blue">the Company </font>could be held     liable for any damages that result and any such <font color="blue">liability</font> could possibly     exceed its resources</td>
    </tr>
    <tr>
      <td>The price of the Company’s <font color="blue"><font color="blue">common stock</font> may</font> be volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of <font color="blue">biotechnology</font> companies, including the     Company, have <font color="blue">historically been highly volatile</font></td>
    </tr>
    <tr>
      <td>The market has, from time     to time, experienced <font color="blue">significant</font> price and <font color="blue">volume fluctuations</font> that are     unrelated to the operating performance of <font color="blue">particular companies</font></td>
    </tr>
    <tr>
      <td>The market     price of the Company’s <font color="blue"><font color="blue">common stock</font> may</font> fluctuate <font color="blue">significant</font>ly due to a     variety of factors, including:       ·     the results of pre<font color="blue">clinical testing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> by <font color="blue">the Company </font>or its     <font color="blue"><font color="blue">competitor</font>s</font>;       ·     <font color="blue">technological</font> <font color="blue">innovations</font> or new <font color="blue">therapeutic</font> products;       ______________________________________________________________________           Page 21       ·     changes in <font color="blue">governmental regulation</font>;         ·     <font color="blue">development</font>s or <font color="blue">disputes concerning</font> the Companyapstas <font color="blue">proprietary rights</font>;       ·     <font color="blue">litigation</font>;       ·     public concern as to the safety of products developed by <font color="blue">the Company </font>or     others;           ·     the Company’s ability to <font color="blue">raise capital</font>;       ·     <font color="blue">comments by securities analysts</font>; and       ·     <font color="blue">general market conditions</font> in the Companyapstas industry</td>
    </tr>
    <tr>
      <td>The  Company’s  existing  <font color="blue">stockholders</font> have <font color="blue">significant</font> control of its     <font color="blue">management</font> and affairs</td>
    </tr>
    <tr>
      <td>The Company’s <font color="blue">executive officers</font> and <font color="blue">directors</font> and holders of <font color="blue">greater than</font>     <font color="blue">five percent</font> of its outstanding <font color="blue">common stock</font>, <font color="blue">together with</font> entities that     may  be deemed <font color="blue">affiliates</font> of, or related to, <font color="blue">such persons</font> or entities,     <font color="blue">beneficially</font> owned <font color="blue">greater than</font> 60 percent of its <font color="blue"><font color="blue">common stock</font> as</font> of <font color="blue">June     </font>30, 2005</td>
    </tr>
    <tr>
      <td>As a result, these <font color="blue">stockholders</font>, acting together, may be able to     control  the  Company’s  <font color="blue">management</font>  and affairs and matters requiring     <font color="blue">stockholder approval</font>, including the election of <font color="blue">directors</font> and approval of     <font color="blue">significant</font> corporate transactions, such as mergers, consolidations or the     sale of <font color="blue">substantially</font> all of our assets</td>
    </tr>
    <tr>
      <td>The interests of the Company’s     existing major <font color="blue">stockholders</font> may not <font color="blue">always coincide with</font> the interests of     other <font color="blue">stockholders</font> and they may take actions in advance of their respective     interests that may be to the detriment of its other <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If the Company’s <font color="blue">stockholders</font> sell substantial amounts of its <font color="blue">common stock</font>,     the <font color="blue">market price</font> of its <font color="blue"><font color="blue">common stock</font> may</font> fall</td>
    </tr>
    <tr>
      <td>If the Company’s <font color="blue">stockholders</font> sell substantial amounts of its <font color="blue">common stock</font>     including <font color="blue">shares issued upon</font> the exercise of <font color="blue">outstanding options</font>, the market     price of its <font color="blue"><font color="blue">common stock</font> may</font> fall</td>
    </tr>
    <tr>
      <td>These <font color="blue">sales also might</font> make it more     <font color="blue">difficult</font> for <font color="blue">the Company </font>to sell equity or equity-related securities in the     future at a time and price that it deems <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>does not expect to <font color="blue">pay dividends on</font> its <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>has never declared or <font color="blue">paid dividends on</font> its <font color="blue">common stock</font> in the     past and it does not expect to <font color="blue">pay dividends on</font> its <font color="blue">common stock</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>______________________________________________________________________       Page 22       <font color="blue">The Company </font>anticipates <font color="blue">future losses</font> and <font color="blue">may never become profitable</font></td>
    </tr>
    <tr>
      <td>Neurogen has     experienced <font color="blue">significant</font> losses since it commenced <font color="blue">operations</font> in 1987</td>
    </tr>
    <tr>
      <td>The     Company’s <font color="blue">accumulated net losses as</font> of <font color="blue">December </font>31, 2005 were <font color="blue">approximately</font>     dlra179 million</td>
    </tr>
    <tr>
      <td>These losses have primarily resulted <font color="blue">from expenses associated</font>     with its research and <font color="blue">development</font> <font color="blue">activities</font>, including pre-clinical and     clinical  trials, and general and <font color="blue">administrative expenses</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>    anticipates  that  its  research  and <font color="blue">development</font> expenses will remain     <font color="blue">significant</font> in the future and it expects to <font color="blue">incur losses over at least</font> the     next <font color="blue">several years</font> as it continues its research and <font color="blue">development</font> efforts,     pre-<font color="blue">clinical testing</font> and <font color="blue"><font color="blue">clinical trial</font>s</font> and, if implemented, <font color="blue">manufacturing</font>,     marketing and <font color="blue">sales programs</font></td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">the Company </font><font color="blue">cannot predict</font> when     it <font color="blue">will become profitable</font>, if at all, and if it does, it may not remain     profitable for any substantial period of time</td>
    </tr>
    <tr>
      <td>If <font color="blue">the Company </font>fails to     achieve <font color="blue">profitability</font> within the timeframe expected <font color="blue">by investors</font>, the market     price of its <font color="blue"><font color="blue">common stock</font> may</font> decline and <font color="blue">consequently</font> its business may not     be sustainable</td>
    </tr>
    <tr>
      <td><font color="blue">Accounting </font><font color="blue">pronouncements may affect</font> the Company’s <font color="blue">future financial position</font>     and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There may be <font color="blue">new accounting pronouncements</font> or <font color="blue">regulatory</font> rulings, which may     have an <font color="blue">affect on</font> the Company’s <font color="blue">future financial position</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2004, the FASB issued SFAS Nodtta 123R, “Share-Based     Payment” (“SFAS 123R”), which replaces SFAS Nodtta 123 and supersedes APB     Opinion Nodtta 25</td>
    </tr>
    <tr>
      <td>SFAS 123R requires all share-based payments to employees,     including  grants  of  <font color="blue">employee <font color="blue">stock options</font></font>, to be recognized in the     <font color="blue">financial statements based on</font> their <font color="blue">fair values</font></td>
    </tr>
    <tr>
      <td>Through <font color="blue">December </font>31, 2005,     <font color="blue">the Company </font>has accounted for grants of <font color="blue">stock options</font> and <font color="blue">restricted stock</font>     to <font color="blue">employees utilizing</font> the <font color="blue">intrinsic value method</font> in <font color="blue">accordance with</font> APB     Opinion Nodtta 25, and, <font color="blue">accordingly</font>, recognized <font color="blue">no compensation expense</font> for the     options when the <font color="blue">option grants</font> have an <font color="blue">exercise price</font> equal to the fair     <font color="blue">market value at</font> the date of grant, and, for <font color="blue">restricted stock</font>, recorded an     <font color="blue">expense over</font> the <font color="blue">vesting periods</font></td>
    </tr>
    <tr>
      <td>Through <font color="blue">December </font>31, 2005, <font color="blue">the Company </font>    followed the disclosure-only provisions of SFAS Nodtta 123 as amended by SFAS     Nodtta  148</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is evaluating the <font color="blue">requirements</font> of SFAS 123R and     anticipate that SFAS 123R will have a material <font color="blue">impact on</font> its results of     <font color="blue">operations</font> and loss per share</td>
    </tr>
  </tbody>
</table>